SHANGHAI, Aug. 10 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc.
(NYSE: WX) today announced shareholder resolutions adopted at its annual general meeting of shareholders held in Hong Kong on August 7, 2009.
(Logo: http://www.prnasia.com/sa/2009/04/01/200904011147.jpg )
At the meeting, WuXi PharmaTech shareholders approved the re-election of incumbent Class B directors Xuesong Leng, Zhaohui Zhang, and Ning Zhao, each to serve a three-year term.
In addition, the WuXi shareholders approved an amendment to the Company's Memorandum of Articles and Association that revises Article 82 so that it no longer requires a Special Resolution be obtained for an office of a Director to be considered vacated.
About WuXi PharmaTech
WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec. For more information, please visit: http://www.wuxiapptec.com .
For more information, please contact:
WuXi PharmaTech (Cayman) Inc.
Ronald Aldridge (for investors)
Director of Investor Relations
Tel: +1-201-585-2048
Email: ir@wuxiapptec.com
Stephanie Liu (for the media)
WuXi PharmaTech (Cayman) Inc.
Tel: +86-21-5046-4362
Email: pr@wuxiapptec.com
